Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: Restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor

Circulation

Volumn 111, Issue 16, 2005, Pages 2073-2085

  Yoon, Young Sup ^a,b   Uchida, Shigeki ^a   Masuo, Osamu ^a   Cejna, Manfred ^a   Park, Jong Seon ^a   Gwon, Hyeon Cheol ^a   Kirchmair, Rudolf ^a   Bahlman, Ferdinand ^a   Walter, Dirk ^a   Curry, Cynthia ^a   Hanley, Allison ^a   Isner, Jeffrey M ^a   Losordo, Douglas W ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Cardiomyopathy; Diabetes; Gene therapy; Growth substances

Indexed keywords

NAKED DNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CARDIOMYOPATHY; CELL DEATH; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; FEMALE; GENE THERAPY; HEART FUNCTION; HISTOPATHOLOGY; HOMEOSTASIS; MALE; MICROVASCULATURE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; STEM CELL; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; FEMALE; GENE THERAPY; HOMEOSTASIS; MALE; MICROCIRCULATION; MYOCARDIUM; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20244378531     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000162472.52990.36     Document Type: Article

References (43)

1. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
2. Beller GA. Coronary heart disease in the first 30 years of the 21st century: challenges and opportunities: the 33rd Annual James B. Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2001;103:2428-2435.
3. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602.
4. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29-34.
5. Schaffer SW, Tan BH, Wilson GL. Development of a cardiomyopathy in a model of noninsulin-dependent diabetes. Am J Physiol. 1985:248(part 2):H179-H185.
6. Regan TJ, Lyons MM, Ahmed SS. et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest. 1977;60:881-899.
7. Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996;28:1661-1669.
8. Litwin SE, Raya TE, Anderson PO, et al. Abnormal cardiac function in the streptozotocin-diabetic rat: changes in active and passive properties of the left ventricle. J Clin Invest. 1990;86:481-488.
9. Fein FS. Diabetic cardiomyopathy. Diabetes Care. 1990;13:1169-1179.
10. Frustaci A, Kajstura J, Chimenli C, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123-1132.
11. Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med. 1980;302:384-388.
12. Sabbah UN, Sharov VG, Lesch M, et al. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem. 1995;147:29-34.
13. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
14. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol. 1999;154:355-363.
15. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation. 2002;105:373-379.
16. Carmeliet P, Ng YS, Nuyens D, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med. 1999;5:495-502.
17. Abraham D, Hofbauer R, Schafer R, et al. Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res. 2000;87:644-647.
18. van den Heuvel AFM, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cordial. 2000;35:19-28.
19. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest. 2001;107:1083-1092.
20. Takahashi N, Seko Y, Noiri E, et al. Vascular endothelial growth factor induces activation and subcellular translocation of focal adhesion kinase (p125FAK) in cultured rat cardiac myocytes. Circ Res. 1999;84:1194-1202.
21. Murase N, Starzl TE, Ye Q, et al. Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation: with particular reference to the liver. Transplantation. 1996;61:1-4.
22. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972.
23. Kawamoto A, Tkebuchava T, Yamaguchi J, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation. 2003;107:461-468.
24. Oh J. Hemodynamic assessment. In: Oh JK SJ, Tajik AJ, eds. The Echo Manual. 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1999:59-71.
25. Reinhardt CP, Dalhberg S, Tries MA, et al. Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique. Am J Physiol Heart Circ Physiol. 2001;280:H108-H116.
26. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101:899-907.
27. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 2000;86:1198-1202.
28. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003;108:3115-3121.
29. Yoon YS, Murayama T, Gravereaux E, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003;111:717-725.
30. 165 following intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123.
31. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation. 1996;94:3281-3290.
32. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure: further knowledge needed. Eur Heart J. 1999;20:789-795.
33. Tasca C, Stefaneanu L, Vasilescu C. The myocardial microangiopathy in human and experimental diabetes mellitus (a microscopic, ultrastructural, morphometric and computer-assisted symbolic-logic analysis). Endocrinologic. 1986;24:59-69.
34. Genda A, Mizuno S, Nunoda S, et al. Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy. Clin Cordial. 1986;9:375-382.
35. Spyridopoulos I, Brogi E, Kearney M, et al. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol. 1997;29:1321-1330.
36. Dimmeler S, Zeiher AM. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res. 2000;87:434-439.
37. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981-990.
38. Miele C, Rochford JJ, Filippa N, et al. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem. 2000;275:21695-21702.
39. Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest. 2003;111:1835-1842.
40. Giordano FJ, Gerber HP, Williams SP, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA. 2001;98:5780-5785.
41. Levy AP, Levy NS, Loscalzo J, et al. Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res. 1995;76:758-766.
42. Murayama T, Tepper O, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol. 2002;30:967-972.
43. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res. 2000;86:1107-1113.